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phosphorylation by a virally encoded
thymidine kinase to exert its antiviral
effect. This mechanism of action would
be advantageous as a therapy for MCV,
which does not possess a functional
thymidine kinase (Gubser et al., 2004).
In fact, acyclovir and foscarnet are
ineffective against CPV because the
virally encoded thymidine kinase does
not catalyze acyclovir or foscarnet (Baker
et al., 2003). In contrast, several studies
have unequivocally shown that CDV is a
highly effective prophylactic and thera-
peutic drug for lethal CPV infection in
mice (Neyts and De Clercq, 2003).
There is increasing interest in effec-
tive antiviral agents because of several
concerns: increasing risk of bioterro-
rism with variola virus as a biologic
weapon, recent outbreak of monkeypox
disease in humans, occasional orf
(sheep pox) infections, and smallpox
vaccination complications, such as
vaccinia gangrenosa and eczema vac-
cinatum (Neyts and De Clercq, 2003).
CDV is one of the most promising
antiviral agents with high efficacy
against the poxvirus family. In a case
of orf, the ecthyma infectiosum lesion
completely disappeared following topi-
cal application of 1% CDV that other-
wise would have led to amputation of
the affected finger (Geerinck et al.,
2001). In another study, antiviral treat-
ment with CDV was more effective than
smallpox vaccination after lethal infec-
tion of monkeys with monkeypox
(Stittelaar et al., 2006). We showed for
the first time that 20–50 mM of CDVpp
inhibited MCV DNA polymerase acti-
vity, providing biochemical support for
CDV as a treatment for MCV lesions.
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TO THE EDITOR
Limited information has been reported
concerning the effects of immune re-
sponses, especially Th2 type, on barrier
dysfunction in vivo. A recent study
reported that IL-4, a Th2 cytokine,
suppresses the enhancement of cera-
mide synthesis and cutaneous per-
meability barrier function induced by
tumor necrosis factor-a and IFN-g in
human epidermal sheets or in the living
skin equivalent, which is a model of
reconstructed skin in vitro. In addition,
IL-4 blocks the recovery of barrier
function and enhancement of ceramide
synthesis after barrier disruption by
acetone treatment in living skin equiva-
lent (Hatano et al., 2005, 2007). How-
ever, living skin equivalent seems
inadequate to observe cutaneous per-
meability barrier function, since the
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early phase of barrier recovery, which
is mainly associated with the release
of materials required for barrier reco-
very from lamellar bodies in true hu-
man skin (Elias and Feingold, 1992),
is not observed in living skin equi-
valent (Koria et al., 2003). An important
role has been reported for the IL-1 gene
family and tumor necrosis factor-a
in the recovery of the permeability
barrier function after acute disrup-
tion (Ye et al., 2002). Among these
factors, IL-1a appears to be the most
potential accelerator of barrier recov-
ery, since it appears in epidermal cells
within 10minutes after barrier pertur-
bation (Wood et al., 1996) and its
deficiency is associated with barrier
dysfunction in aged mice, unlike tumor
necrosis factor-a (Ye et al., 2002). In
addition, exogenous IL-1a accelerates
the recovery of barrier function in vivo
(Barland et al., 2004). This study
examined the effect of IL-4 on the
recovery of permeability barrier func-
tion and its modification by IL-1a
in vivo.
This study was approved by the
Ethics of Animal Experimentation Com-
mittee of Oita University. Female
C57BL/6 mice were used at 6 or 20
weeks of age with normal, well-charac-
terized immune function to examine
the effect of IL-4. The flanks of the mice
were shaved 5 days before barrier
disruption according to the protocol
described previously using hairy mice
(Barland et al., 2004) with some mod-
ifications. Barrier disruption was
achieved by sequential applications of
cellophane tape (Nichiban, Tokyo,
Japan) (4–5 times) or by acetone appli-
cation. The procedure was stopped
when the transepidermal water loss
reached 80–100 g per m2 per hour as
measured with a skin evaporative water
recorder (Tewameters TM210, Cour-
age & Khazawa, Ko¨ln, Germany). Mice
were injected intradermally with 50 ng
of IL-1a (Peprotech EC, London, UK)
and/or various doses of IL-4
(100 ng–0.001 pg; Peprotech) in 50 ml
of Hanks Balanced Salt Solution or
HBSS alone into the flank immediately
after barrier disruption. In some experi-
ments, 100 ng of IL-4 in 100ml of HBSS
or HBSS alone was injected intrave-
nously immediately after barrier
disruption. Barrier recovery was mon-
itored immediately after and, at 3, 6,
and 24 hours after barrier disruption.
The recovery rate was calculated as
described previously (Chou et al.,
2005).
The intradermal injection of 100 ng
of IL-4 inhibited the recovery of the
barrier function at 3, 6, and 24 hours
after barrier disruption by tape stripping
(Figure 1a). The inhibitory effect was
almost lost at 24 hours in some experi-
ments (data not shown). The intrader-
mal injection of IL-4 (100 ng) did not
affect transepidermal water loss on non-
treated skin (data not shown). The
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Figure 1. Administration of intradermal and intravenous IL-4 suppresses cutaneous barrier recovery
after tape stripping or acetone treatment. Transepidermal water loss was measured before and at 0, 3, 6,
and 24hours after barrier disruption and barrier recovery was calculated as described previously
(Chou et al., 2005). (a) Inhibitory effect of IL-4 on barrier recovery after barrier disruption by tape stripping.
The mice received either an intradermal (i.c.) or intravenous (i.v.) injection of 100ng of IL-4 in 50 or 100ml
of HBSS or HBSS alone (control) immediately after barrier disruption by tape stripping (n¼8 mice per
group). (b) Inhibitory effect of IL-4 on barrier recovery after barrier disruption by acetone treatment.
The mice received an intradermal injection of 100ng of IL-4 in 50ml of HBSS or HBSS alone (control)
immediately after barrier disruption by acetone treatment (n¼ 8 mice per group). (c) Threshold dose of IL-4
to be required to inhibit the barrier recovery. The mice received an intradermal administration of 0.001,
0.01, 0.1, 1, and 10pg of IL-4 in 50ml of HBSS or HBSS alone (control) immediately after barrier disruption
by tape stripping (n¼ 6 mice per group). The barrier recovery rate at 3 hours after tape stripping is shown.
All experiments were performed under conditions of controlled temperature (22–251C) and humidity
(25–40%). The mean values for each group of barrier recovery percent are presented with s.e.m. Data were
subjected to analysis using Student’s t-test. Po0.05 was regarded as statistically significant. Data shown are
representative of at least two independent experiments. NS, not significant.
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intravenous injection of IL-4 (100 ng)
immediately after barrier disruption
partially inhibited the recovery of bar-
rier function (Figure 1a). A similar
inhibitory effect of the intradermal
injection of IL-4 was observed at 3, 6,
and 24 hours after barrier disruption by
topical application of acetone (Figure
1b). Histological examination of tissue
stained with hematoxylin and eosin
stain did not reveal any inflammatory
reactions in the skin treated with IL-4 at
3 and 6 hours after barrier disruption
(data not shown). The threshold dose of
IL-4 required to inhibit the recovery of
the barrier function was then deter-
mined. Surprisingly, a very low dose of
IL-4, between 0.01 and 0.1 pg
(0.2–2 pgml1), inhibited the recovery
of barrier function (Figure 1c). To
explore the mechanism of the inhibitory
effect of IL-4, the effect of simultaneous
injection of IL-4 on the accelerating
effect of IL-1a on the recovery of barrier
function was observed. The administra-
tion of 100 ng (data not shown) and
0.1 pg of IL-4 antagonized the accele-
rating effect of IL-1a (Figure 2).
This study clearly showed the in-
hibitory effect of IL-4 on the barrier
recovery, especially in the early phase,
in vivo and supports the hypothesis that
Th2 cytokines may impair the barrier
recovery in cutaneous inflammatory
diseases. Moreover, the successful in-
hibition by intradermal injection of IL-4
at very low dose and intravenous
injection of IL-4 suggests that not only
local synthesis but also systemic pro-
duction of IL-4 might be able to affect
the cutaneous barrier function. The
steps in the barrier recovery process
that are inhibited by IL-4 in vivo remain
to be clarified. IL-4 is likely to inhibit
the recovery of barrier function by
interference with the effects of IL-1a,
such as the stimulation of epidermal
DNA and lipid synthesis in cultured
keratinocytes (Barland et al., 2004). The
similarity between the time course of
the effect of IL-4 and that of IL-1a
(Barland et al., 2004) in the barrier
recovery also suggests that IL-1a and IL-
4 might work on a common target in
the homeostasis of cutaneous barrier
function.
Finally, this study suggests the pos-
sibility that Th2 cytokines might con-
tribute to the pathogenesis of cutaneous
inflammatory diseases in which not
only Th1 but also Th2 type inflamma-
tion is involved via the impaired
recovery of the barrier function. Further
studies to explore this concept using
another experimental model are thus
required.
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Figure 2. Intradermal administration of IL-4 suppressed the accelerating effect of IL-1a on the recovery
of cutaneous barrier function. The mice received an intradermal injection of 0.1 pg of IL-4 and/or
50 ng of IL-1a in 50 ml of HBSS or HBSS alone (control) immediately after barrier disruption by tape
stripping. Transepidermal water loss was measured before and at 0, 3, 6, and 24 hours after barrier
disruption and the percent barrier recovery was calculated (n¼6 mice per group). Experiments were
performed under conditions of controlled temperature (22–251C) and humidity (25–40%). The mean
values for each group of barrier recovery percent are presented with s.e.m. The statistical analyses
performed are as described in the legend of Figure 1. Data shown are representative of two independent
experiments. NS, not significant.
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